Instant Report

Date: 20-Nov-2020

SyntheticMR Announces Submission Of 510(k) To US FDA For Musculoskeletal Solutions Package, SyMRI MSK

SyntheticMR, an innovative software solutions company for magnetic resonance imaging (MRI), announced the company filed a 510(k) submission for its musculoskeletal solutions package, SyMRI MSK.

“We are thrilled to receive 510(k) pending status for SyMRI MSK,” said Ulrik Harrysson, CEO, SyntheticMR. “In today’s environment, there is a clear demand for quantitative solutions in the musculoskeletal market and we believe that we have a unique opportunity to enable physicians to make better, more informed decisions using quantitative imaging in MSK applications.”

Like its neuro counterpart, the SyMRI MSK package provides radiologists a solution-based approach by offering 6-minute scans that can drastically improve patient throughput, produce a range of contrast-weight­ed images, as well as quantitative T1, T2, and PD maps for both clinical and research practices for all MSK anatomies and joints – including spine.

“Most people will experience joint or back pain at some point of their lives,” explains Kyle Frye, president of SyntheticMR US. “While it’s routine to use MRI to help physicians diagnose issues relative to the knee, shoulder, ankle, and spine, now we are taking it to the next level by providing a quantitative approach. In other words, we’re helping move from a subjective environment to one that is objective. And that’s something we are truly excited about.”

SyMRI MSK uses a unique scanning sequence to measure the ab­solute properties of the anatomy and joins the SyntheticMR’s growing portfolio of quantitative software solutions, which includes SyMRI NEURO.

SyntheticMR AB develops and markets innovative software solutions for magnetic resonance imaging (MRI). SyntheticMR AB has developed SyMRI, delivering multiple, adjustable contrast images and quantitative data from a single 6-minute scan.